Current Status and Future Prospects of Perinatal Stem Cells
Grupo de Medicina Regenerativa, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Avda. Cordoba s/n, 28041 Madrid, Spain
*
Author to whom correspondence should be addressed.
Genes 2021, 12(1), 6; https://doi.org/10.3390/genes12010006
Received: 16 November 2020 / Revised: 18 December 2020 / Accepted: 20 December 2020 / Published: 23 December 2020
(This article belongs to the Special Issue Application Status and Development Prospects of Stem Cells)
The placenta is a temporary organ that is discarded after birth and is one of the most promising sources of various cells and tissues for use in regenerative medicine and tissue engineering, both in experimental and clinical settings. The placenta has unique, intrinsic features because it plays many roles during gestation: it is formed by cells from two individuals (mother and fetus), contributes to the development and growth of an allogeneic fetus, and has two independent and interacting circulatory systems. Different stem and progenitor cell types can be isolated from the different perinatal tissues making them particularly interesting candidates for use in cell therapy and regenerative medicine. The primary source of perinatal stem cells is cord blood. Cord blood has been a well-known source of hematopoietic stem/progenitor cells since 1974. Biobanked cord blood has been used to treat different hematological and immunological disorders for over 30 years. Other perinatal tissues that are routinely discarded as medical waste contain non-hematopoietic cells with potential therapeutic value. Indeed, in advanced perinatal cell therapy trials, mesenchymal stromal cells are the most commonly used. Here, we review one by one the different perinatal tissues and the different perinatal stem cells isolated with their phenotypical characteristics and the preclinical uses of these cells in numerous pathologies. An overview of clinical applications of perinatal derived cells is also described with special emphasis on the clinical trials being carried out to treat COVID19 pneumonia. Furthermore, we describe the use of new technologies in the field of perinatal stem cells and the future directions and challenges of this fascinating and rapidly progressing field of perinatal cells and regenerative medicine.
View Full-Text
Keywords:
placenta; perinatal tissues; umbilical cord tissue/blood; chorion; decidua; amniotic fluid/membrane; regenerative medicine; mesenchymal stromal cells; nanomedicine; COVID-19
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Torre, P.d.l.; Flores, A.I. Current Status and Future Prospects of Perinatal Stem Cells. Genes 2021, 12, 6. https://doi.org/10.3390/genes12010006
AMA Style
Torre Pdl, Flores AI. Current Status and Future Prospects of Perinatal Stem Cells. Genes. 2021; 12(1):6. https://doi.org/10.3390/genes12010006
Chicago/Turabian StyleTorre, Paz d.l.; Flores, Ana I. 2021. "Current Status and Future Prospects of Perinatal Stem Cells" Genes 12, no. 1: 6. https://doi.org/10.3390/genes12010006
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit